Cross Cancer Institute ( Site 0400)

Edmonton, Alberta T6G 1Z2

0 studies enrolling now · 1 studies all time

What they study most

Non-small Cell Lung Cancer

Studies at this site

• Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) — Completed